Assort Health Raises $120M in Series C Funding Round

The round also saw participation from Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.

The company plans to use the funding to expand its operations and continue developing its technology and products.

Healthcare providers spend nearly twice as much on administrative work as they do on direct patient care, creating a significant burden across the industry. Assort was founded to address this problem by improving the patient experience at the first point of contact.

Read More:AquaPoro Raises $5M in Seed Funding Led by Breakout Ventures

The company started with a voice AI agent for scheduling specialty appointments and has since expanded into a broader platform that supports scheduling, intake forms, referrals, document processing, medication refills, eligibility checks, lab requests, and payments. Its platform has been trained using more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating a large proprietary dataset for specialty healthcare.

Synapse, Assort’s proprietary AI model, learns how specialty healthcare workflows operate across different customers and automatically creates the tests, simulations, and scenarios needed to handle complex cases. This allows even highly customized provider workflows to be deployed with strong automation and high resolution rates. As more customers use the platform, the system continues to improve. Over the past 15 months, Assort has increased its revenue by 20 times.

"Specialty care is a different discipline than most AI vendors realize, and that difficulty only compounds at large health systems. It's exactly what we built Synapse for. Our proprietary model learns the patterns of specialty workflows and gets sharper with every deployment, and that's what lets us move past answering calls to automating the entire patient journey. That depth is our advantage, and Synapse is the foundation that lets us build faster than anyone in the market," said Jeffery Liu, Founder and Co-CEO of Assort Health.

"We evaluated every AI solution on the market. Assort was the only true platform," said Dr. Parinita Amin, CEO of MDCS Dermatology. "It runs the full patient journey as one connected system, from referrals and document processing to intake, care gap closure, real-time eligibility, and payments. The difference is memory. Everyone else automates one piece and forgets the rest. Assort remembers every patient across every interaction and connects it all into one conversation. Our automation rate climbs every quarter as they execute against an ambitious roadmap, and the gap between Assort and everyone else keeps widening."

"This market is going to consolidate in the same way every other one has. Provider groups know it, and the smart ones aren't buying another point solution. They want one partner with the capital and the engineering depth to transform how they operate over the long run. That's what we built. Our engineers learn from hundreds of customers and build every implementation for the specific practice in front of them. We have now raised over $220M to make that engine better," said Jon Wang, Founder and Co-CEO of Assort Health.

About Assort Health

Founded in 2023 by Jeff Liu and Jon Wang, Assort Health provides AI agents that support the patient journey, including scheduling, intake, referrals, forms, medication refills, and payments. Built on more than 190 million specialty patient interactions, the platform helps healthcare providers automate complex workflows and improve efficiency. Assort works with multi-site practices, specialty groups and health systems. Customers report higher appointment volumes, increased staff capacity and strong patient satisfaction.

Read More:CentSight Raises $1.5M in Pre-Seed Funding Round